Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiactransplant recipients with chronic renal failure

Transplantation

Volumn 77, Issue 4, 2004, Pages 568-574

  Groetzner, Jan ^a   Meiser, Bruno ^a   Landwehr, Peter ^a   Buehse, Lucia ^a   Mueller, Markus ^a   Kaczmarek, Ingo ^a   Vogeser, Michael ^a   Daebritz, Sabine ^a   Ueberfuhr, Peter ^a   Reichart, Bruno ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; CYSTATIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; CALCINEURIN; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TIME FACTORS;

EID: 10744231167     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000103740.98095.14     Document Type: Article

References (24)

1. Hosenpud JD, Bennett LE. Cyclosporine versus tacrolimus in heart transplantation: an ISHLT/UNOS registry analysis. J Heart Lung Transplant 2001; 20(2): 161.
2. John R, Rajasinghe HA, Chen JM, et al. Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy. Ann Thorac Surg 2001; 72: 440.
3. Van Gelder T, Balk AH, Zietse R, et al. Renal insufficiency after heart transplantation: a case control study. Nephrol Dial Transplant 1998; 13: 2322.
4. Frimat L, Villemont JP, Cornier L, et al: Treatment of end-stage renal failure after heart transplantation. Nephrol Dial Transplant 1998; 13: 2905.
5. Groetzner J, Meiser BM, Schirmer J, et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? Transplant Proc 2001; 33(1): 1461.
6. Jayasena SD, Riaz A, Lewis CM, et al. Outcome in patients with end-stage renal disease following heart or heart-lung transplantation receiving peritoneal dialysis. Nephrol Dial Transplant 2001; 16: 1681.
7. Davies D, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 2000; 12: SS11.
8. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporin-associated end stage nephropathy after cardiac transplantation: incidence and prognosis. Transplantation 1997; 63: 664.
9. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143.
10. Keogh AM, and the Sirolimus Cardiac Transplant Trial Group. Sirolimus immunotherapy reduces the rates of cardiac allograft rejection: 6-month results from a phase2, open-label study. Am J Transplant 2002; 3(2): S246.
11. Vu MD, Qi S, Xu D. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 1998; 66(12): 1575.
12. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21(5): 540.
13. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1975; 16(1): 31.
14. Vogeser M, Fleischer C, Groetzner J, et al. Quantification of sirolimus by liquid chromatography-tandem mass spectrometry using on-line solid-phase extraction. Clin Chem Lab Med 2002; 40(1): 40.
15. Aleksic I, Baryalei M, Busch T, et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000; 27: 1586.
16. Tedoriya T, Keogh AM, Kusano K, et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 9: 976.
17. Schlitt HJ, Barkmann A, Schmidt HJ, et al. Replacement of calcineurin inhibitors with MMF in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587.
18. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72(5): 777.
19. Meiser BM, Schirmer J, Schmidt D, et al. Complete conversion of immunosuppression from cyclosporine to mycophenolatemofetil in patients with renal failure after HTx. Transplantation 1999; 67: 111.
20. Kreis H; Cisterne JM; Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69(7): 1252.
21. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7(8): 701.
22. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70(6): 969.
23. Keogh AM, and The Sirolimus Cardiac Transplant Trial Group. Sirolimus immunotherapy significantly reduces the progression of graft vessel disease after cardiac transplantation: 6-Month results from a phase 2, open-label study. Transplantation 2002; 12: 123.
24. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic Acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; (59): 655.